PTPRC and neoplasm: The study will include analyses of CD45+CD4+CD25+FoxP3+T cells and CD25+FoxP3+T cells in the peripheral blood, as well as the distribution of CD8+ and Foxp3+ (immunoreactive/suppressor) T cells in different regions of tumor lesions.